Physician profile
Coleman E Altman
NPI 1003806928
$10,214.87
in general payments reported to CMS, 2019-2025
47 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,056 · 2020: $629 · 2021: $158 · 2022: $2,113 · 2023: $2,273 · 2024: $1,656 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,119 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,118.69 |
| Education | $139.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,238.22 | 2019-2025 | Ilumya, Winlevi |
| Abbvie INC. | $1,142.63 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $955.19 | 2019-2025 | |
| Amgen INC. | $839.79 | 2019-2025 | Otezla, Otezla, Enbrel |
| Janssen Biotech, INC. | $725.98 | 2019-2025 | Tremfya |
| Ucb, INC. | $523.56 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $474.69 | 2019-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $452.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $451.89 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $436.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $367.29 | 2022-2025 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $353.19 | 2019-2025 | Clindacin Etz, Neo-Synalar, Genadur |
| Lilly USA, LLC | $342.51 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $204.01 | 2019-2024 | Arazlo, Cabtreo, Jublia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.72 | 2022-2025 | Spevigo |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coleman Altman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.